| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Keren Wood, Idit Maharshak, Yosef Koronyo, Maya Koronyo-Hamaou. [THE RETINA AS A TOOL FOR EARLY DIAGNOSIS OF ALZHEIMER DISEASE]. Harefuah. vol 161. issue 8. 2022-08-18. PMID:35979573. |
alzheimer's disease is a neurodegenerative disease pathologically characterized by accumulation of abnormal amyloid-beta (aβ) and tau proteins. |
2022-08-18 |
2023-08-14 |
Not clear |
| Keren Wood, Idit Maharshak, Yosef Koronyo, Maya Koronyo-Hamaou. [THE RETINA AS A TOOL FOR EARLY DIAGNOSIS OF ALZHEIMER DISEASE]. Harefuah. vol 161. issue 8. 2022-08-18. PMID:35979573. |
indeed, evidence of aβ plaques and abnormal tau proteins in the retina of alzheimer's patients has been reported. |
2022-08-18 |
2023-08-14 |
Not clear |
| Majedul Islam, Fengyun Shen, Deepika Regmi, Katherine Petersen, Md Raza Ul Karim, Deguo D. Tau liquid-liquid phase separation: At the crossroads of tau physiology and tauopathy. Journal of cellular physiology. 2022-08-18. PMID:35980344. |
abnormal deposition of tau in neurons is a hallmark of alzheimer's disease and several other neurodegenerative disorders. |
2022-08-18 |
2023-08-14 |
Not clear |
| David G Coughlin, Vanessa S Goodwill, Heidi G Standke, Yongya Kim, Nicolas Coley, Donald P Pizzo, Douglas Galasko, Allison Kraus, Annie Hinike. Selective tau seeding assays and isoform-specific antibodies define neuroanatomic distribution of progressive supranuclear palsy pathology arising in Alzheimer's disease. Acta neuropathologica. 2022-08-18. PMID:35980456. |
selective tau seeding assays and isoform-specific antibodies define neuroanatomic distribution of progressive supranuclear palsy pathology arising in alzheimer's disease. |
2022-08-18 |
2023-08-14 |
Not clear |
| Anton Bespalov, Jean-Philippe Courade, Leonard Khiroug, Georg C Terstappen, Yipeng Wan. A call for better understanding of target engagement in Tau antibody development. Drug discovery today. 2022-08-16. PMID:35973661. |
disappointment with the first generation of clinical tau antibodies in alzheimer's disease has highlighted the challenges in understanding whether an antibody can reach or affect the target in the compartment where it is involved in pathological processes. |
2022-08-16 |
2023-08-14 |
Not clear |
| Eva Baerends, Katia Soud, Jonas Folke, Anna-Kathrine Pedersen, Simon Henmar, Lisa Konrad, Matthew D Lycas, Yuki Mori, Bente Pakkenberg, David P D Woldbye, Oksana Dmytriyeva, Stanislava Pankratov. Modeling the early stages of Alzheimer's disease by administering intracerebroventricular injections of human native Aβ oligomers to rats. Acta neuropathologica communications. vol 10. issue 1. 2022-08-16. PMID:35974377. |
alzheimer's disease (ad) is a progressive and irreversible neurodegenerative disease characterized by the accumulation of aggregated amyloid beta (aβ) and hyperphosphorylated tau along with a slow decline in cognitive functions. |
2022-08-16 |
2023-08-14 |
human |
| Suzanne Lam, Anne-Sophie Hérard, Susana Boluda, Fanny Petit, Sabiha Eddarkaoui, Karine Cambon, Jean-Luc Picq, Luc Buée, Charles Duyckaerts, Stéphane Haïk, Marc Dhenai. Pathological changes induced by Alzheimer's brain inoculation in amyloid-beta plaque-bearing mice. Acta neuropathologica communications. vol 10. issue 1. 2022-08-16. PMID:35974399. |
alzheimer's disease (ad) is characterized by intracerebral accumulations of extracellular amyloid-β (aβ) plaques and intracellular tau pathology that spread in the brain. |
2022-08-16 |
2023-08-14 |
mouse |
| Yuanyuan L. Early increase of cerebrospinal fluid 14-3-3ζ protein in the alzheimer's disease continuum. Frontiers in aging neuroscience. vol 14. 2022-08-15. PMID:35966774. |
the earlier research has shown that the 14-3-3ζ is increased in neurofibrillary tangles (nfts) of human alzheimer's disease (ad) brains and stimulates the tau phosphorylation. |
2022-08-15 |
2023-08-14 |
human |
| Kevin A Murray, Carolyn J Hu, Sarah L Griner, Hope Pan, Jeannette T Bowler, Romany Abskharon, Gregory M Rosenberg, Xinyi Cheng, Paul M Seidler, David S Eisenber. De novo designed protein inhibitors of amyloid aggregation and seeding. Proceedings of the National Academy of Sciences of the United States of America. vol 119. issue 34. 2022-08-15. PMID:35969734. |
known as amyloid, these fibrillar aggregates include proteins such as tau and amyloid-β (aβ) in alzheimer's disease (ad) and alpha-synuclein (αsyn) in parkinson's disease (pd). |
2022-08-15 |
2023-08-14 |
Not clear |
| Sivaprakasam R Saroja, Kirill Gorbachev, Tcw Julia, Alison M Goate, Ana C Pereir. Astrocyte-secreted glypican-4 drives APOE4-dependent tau hyperphosphorylation. Proceedings of the National Academy of Sciences of the United States of America. vol 119. issue 34. 2022-08-15. PMID:35969759. |
tau protein aggregates are a major driver of neurodegeneration and behavioral impairments in tauopathies, including in alzheimer's disease (ad). |
2022-08-15 |
2023-08-14 |
Not clear |
| António J Figueira, Guilherme G Moreira, Joana Saavedra, Isabel Cardoso, Cláudio M Gome. Tetramerization of the S100B chaperone spawns a Ca Journal of molecular biology. 2022-08-15. PMID:35970403. |
tetramerization of the s100b chaperone spawns a ca alzheimer's disease (ad) hallmarks include the aggregation of amyloid-β (aβ), tau and neuroinflammation promoted by several alarmins. |
2022-08-15 |
2023-08-14 |
Not clear |
| Yue Dong, Hanqiao Yu, Xueqi Li, Kelong Bian, Yayuan Zheng, Mingrui Dai, Xuejian Feng, Yao Sun, Yu He, Bin Yu, Haihong Zhang, Jiaxin Wu, Xianghui Yu, Hui Wu, Wei Kon. Hyperphosphorylated tau mediates neuronal death by inducing necroptosis and inflammation in Alzheimer's disease. Journal of neuroinflammation. vol 19. issue 1. 2022-08-15. PMID:35971179. |
hyperphosphorylated tau mediates neuronal death by inducing necroptosis and inflammation in alzheimer's disease. |
2022-08-15 |
2023-08-14 |
Not clear |
| Raffaella Migliaccio, Federica Cacciaman. The temporal lobe in typical and atypical Alzheimer disease. Handbook of clinical neurology. vol 187. 2022-08-14. PMID:35964987. |
alzheimer disease (ad) is defined neuropathologically by abnormal extra-cellular β-amyloid plaques combined with intraneuronal tau aggregation. |
2022-08-14 |
2023-08-14 |
Not clear |
| Raffaella Migliaccio, Federica Cacciaman. The temporal lobe in typical and atypical Alzheimer disease. Handbook of clinical neurology. vol 187. 2022-08-14. PMID:35964987. |
in typical amnestic late-onset alzheimer's disease (>65 years old; load), tau pathology gradually spreads to the brain from the medial temporal lobe (mtl). |
2022-08-14 |
2023-08-14 |
Not clear |
| Philip S Insel, Christina B Young, Paul S Aisen, Keith A Johnson, Reisa A Sperling, Elizabeth C Mormino, Michael C Donohu. Tau positron emission tomography in preclinical Alzheimer's disease. Brain : a journal of neurology. 2022-08-13. PMID:35962782. |
tau positron emission tomography in preclinical alzheimer's disease. |
2022-08-13 |
2023-08-14 |
human |
| Philip S Insel, Christina B Young, Paul S Aisen, Keith A Johnson, Reisa A Sperling, Elizabeth C Mormino, Michael C Donohu. Tau positron emission tomography in preclinical Alzheimer's disease. Brain : a journal of neurology. 2022-08-13. PMID:35962782. |
using three large cohorts of cognitively unimpaired older adults, the anti-amyloid treatment in asymptomatic alzheimer's and companion study, longitudinal evaluation of amyloid risk and neurodegeneration (n = 447), the alzheimer's disease neuroimaging initiative (n = 420), and the harvard aging brain study (n = 190), we attempt to identify regions with high rates of tau accumulation and estimate how these rates evolve over a continuous spectrum of baseline amyloid deposition. |
2022-08-13 |
2023-08-14 |
human |
| Philip S Insel, Christina B Young, Paul S Aisen, Keith A Johnson, Reisa A Sperling, Elizabeth C Mormino, Michael C Donohu. Tau positron emission tomography in preclinical Alzheimer's disease. Brain : a journal of neurology. 2022-08-13. PMID:35962782. |
while the entorhinal cortex plays a central role in the early appearance of tau, it may be the inferior temporal cortex that is the critical region for rapid tau accumulation in preclinical alzheimer's disease. |
2022-08-13 |
2023-08-14 |
human |
| Murali Vijayan, P Hemachandra Redd. Reduced VDAC1, Maintained Mitochondrial Dynamics and Enhanced Mitochondrial Biogenesis in a Transgenic Tau Mouse Model of Alzheimer's Disease. International journal of molecular sciences. vol 23. issue 15. 2022-08-12. PMID:35955694. |
reduced vdac1, maintained mitochondrial dynamics and enhanced mitochondrial biogenesis in a transgenic tau mouse model of alzheimer's disease. |
2022-08-12 |
2023-08-14 |
mouse |
| Tapan Behl, Rashita Makkar, Aayush Sehgal, Neelam Sharma, Sukhbir Singh, Mohammed Albratty, Asim Najmi, Abdulkarim M Meraya, Simona Gabriela Bunga. Insights into the Explicit Protective Activity of Herbals in Management of Neurodegenerative and Cerebrovascular Disorders. Molecules (Basel, Switzerland). vol 27. issue 15. 2022-08-12. PMID:35956919. |
the treatment employed in management of these debilitating neurodegenerative disorders, such as parkinson's disease (which mainly involves the loss of dopaminergic neurons in the nigrostriatal region), alzheimer's disease (which arises due to accumulation of tau proteins causing diffusive atrophy in the brain), huntington's disease (which involves damage of striatal and spinal neurons, etc. |
2022-08-12 |
2023-08-14 |
Not clear |
| Leian Chen, Xiaoqian Niu, Yuye Wang, Shuang Lv, Xiao Zhou, Ziyuan Yang, Dantao Pen. Plasma tau proteins for the diagnosis of mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis. Frontiers in aging neuroscience. vol 14. 2022-08-12. PMID:35959295. |
plasma tau proteins for the diagnosis of mild cognitive impairment and alzheimer's disease: a systematic review and meta-analysis. |
2022-08-12 |
2023-08-14 |
Not clear |